TRIS PHARMA, INC.

2024 saw over 25 pediatric FDA approvals, including givinostat for Duchenne muscular dystrophy, FluMist for influenza, clonidine hydrochloride for ADHD, dupilumab for eosinophilic esophagitis, epinephrine nasal spray for anaphylaxis, and roflumilast cream for atopic dermatitis.

Onyda XR, a liquid non-stimulant ADHD medication, became available nationwide on October 1. FDA approved it on May 24 for pediatric patients aged 6 and older, either as monotherapy or adjunctive therapy to CNS stimulants. Developed by Tris Pharma using LiquiXR® technology, Onyda XR is a centrally acting alpha2-adrenergic agonist, similar to Guanfacine and clonidine. Non-stimulant medications like Onyda XR are nearly as effective as stimulants in improving executive function, according to a May meta-analysis. Combination therapy with stimulants is increasingly popular for extended symptom coverage and reduced side effects.

Onyda XR, the first liquid nonstimulant for ADHD, is now available in the US. SGLT2i reduces hospitalizations and mortality in heart failure patients. Stigma hinders pharmacists with substance use disorder from seeking help. Pharmacy technicians could enhance public health by becoming vaccine champions. Cocaine and cannabis use significantly increase cardiovascular events.

Clonidine hydrochloride (Onyda XR), the first liquid, non-stimulant for ADHD, is now available in the US for pediatric patients aged 6 and older. Approved by the FDA in May 2024, it can be used as monotherapy or adjunctive therapy to a stimulant. Onyda XR addresses the need for diverse treatment options for ADHD, especially for those who struggle with pill intake or require longer-acting therapy.

Tris Pharma launches ALLEVIATE-1 and ALLEVIATE-2 phase 3 trials for cebranopadol, a dual-NMR agonist targeting NOP and MOP receptors to reduce opioid side effects without compromising pain relief. Trials will enroll over 500 patients post-surgery, aiming for FDA approval.